Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Appendicitis
Clinical narrative: appendicitis 5 days after their second dose; This spontaneous case was reported by a patient and describes the occurrence of APPENDICITIS (appendicitis 5 days after their second dose) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026B21A and 027A21A) for COVID-19 vaccination.     Concurrent medical conditions included Type II diabetes mellitus (diabetes 2), Blood pressure abnormal, Blood cholesterol abnormal and Kidney disorder. Concomitant products included ATORVASTATIN, METFORMIN and INSULIN for an unknown indication.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced APPENDICITIS (appendicitis 5 days after their second dose) (seriousness criterion medically significant). At the time of the report, APPENDICITIS (appendicitis 5 days after their second dose) had resolved.            Concomitant medications reported included unspecified blood pressure medication, kidney treatment medication, cholesterol treatment medications, blood thinner medication and antidiabetic medication. No vaccines were given within 1 month, prior to Moderna COVID-19 vaccine. Patient was not allergic to medications, food and other products. Patient never had COVID + test or diagnosis. Patient stated that  they got appendicitis 5 days after their second dose of the Moderna COVID-19 vaccine. No treatment medications were reported.  Company comment  This is a spontaneous case concerning a 69 year old male patient with no relevant medical history reported, who experienced the unexpected, serious (medically significant) AESI of Appendicitis (appendicitis 5 days after their second dose) 05 days after receiving the 2 dose of mRNA-1273 vaccine in the covid 19 vaccination series. Concurrent medical condition Type II diabetes mellitus could be considered as a risk factor to the event. No details on labs, diagnostic tests, concomitant medications and treatment were provided. The event had resolved. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Events´ seriousness assessed as per medical judgement.   This case was linked to MOD-2022-597351 (Patient Link).; Sender's Comments: This is a spontaneous case concerning a 69 year old male patient with no relevant medical history reported, who experienced the unexpected, serious (medically significant) AESI of Appendicitis (appendicitis 5 days after their second dose) 05 days after receiving the 2 dose of mRNA-1273 vaccine in the covid 19 vaccination series. Concurrent medical condition Type II diabetes mellitus could be considered as a risk factor to the event. No details on labs, diagnostic tests, concomitant medications and treatment were provided. The event had resolved. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Events´ seriousness assessed as per medical judgement.